Sinopharm Group Co. Ltd. (HKG:1099)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
17.38
-0.27 (-1.53%)
Jul 31, 2026, 4:08 PM HKT

Sinopharm Group Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
574,272575,168584,508596,570552,148521,051
Revenue Growth
-0.80%-1.60%-2.02%8.04%5.97%14.16%
Cost of Revenue
533,118533,496540,253548,058504,713477,001
Gross Profit
41,15441,67244,25548,51247,43444,051
Selling, General & Admin
23,68724,02625,58226,16124,91423,210
Other Operating Expenses
-497.7-428.51-468.62-582.01-676.16-589.19
Operating Expenses
24,01824,44226,43626,19324,67023,067
Operating Income
17,13617,23017,81922,31822,76420,984
Interest Expense
-2,230-2,293-2,724-2,946-3,509-3,745
Interest & Investment Income
459.24510.18621.38783.41555.82590.55
Earnings From Equity Investments
1,2331,2331,1991,1071,0671,070
Currency Exchange Gain (Loss)
0.930.93-15.62-9.98-2.39-10.51
Other Non Operating Income (Expenses)
-385.15-415.01-331.44-291.8-464.32-339.47
EBT Excluding Unusual Items
16,21416,26516,56820,96220,41118,549
Impairment of Goodwill
-459.73-459.73-931.2-27.02-38.98-396.06
Gain (Loss) on Sale of Investments
-1,046-1,046-1,650-1,986-1,892-1,094
Gain (Loss) on Sale of Assets
19.420.5379.91492.313.1165.87
Asset Writedown
-93.77-101.17-174.76-27.88-16.81-210.8
Other Unusual Items
120.81120.81108.0898.9297.8188.71
Pretax Income
14,75514,80014,00119,51218,56417,003
Income Tax Expense
3,9893,9653,5774,5024,2183,938
Earnings From Continuing Operations
10,76510,83410,42415,01014,34513,065
Minority Interest in Earnings
-3,653-3,679-3,374-5,956-5,820-5,306
Net Income
7,1127,1557,0509,0548,5267,759
Net Income to Common
7,1127,1557,0509,0548,5267,759
Net Income Growth
0.36%1.49%-22.13%6.19%9.89%7.95%
Shares Outstanding (Basic)
3,1313,1213,1213,1213,1173,121
Shares Outstanding (Diluted)
3,1313,1213,1213,1213,1173,121
Shares Change
0.24%--0.12%-0.12%0.30%
EPS (Basic)
2.272.292.262.902.742.49
EPS (Diluted)
2.272.292.262.902.742.49
EPS Growth
-0.00%1.37%-22.10%6.02%10.02%7.63%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
14,71712,64210,07515,21318,8377,234
Free Cash Flow Per Share
4.704.053.234.886.042.32
Dividend Per Share
0.6900.6900.6800.8700.8200.750
Dividend Growth
1.47%1.47%-21.84%6.10%9.33%8.70%
Gross Margin
7.17%7.25%7.57%8.13%8.59%8.45%
Operating Margin
2.98%3.00%3.05%3.74%4.12%4.03%
Profit Margin
1.24%1.24%1.21%1.52%1.54%1.49%
Free Cash Flow Margin
2.56%2.20%1.72%2.55%3.41%1.39%
EBITDA
19,14119,26419,97124,40424,77722,896
EBITDA Margin
3.33%3.35%3.42%4.09%4.49%4.39%
D&A For EBITDA
2,0052,0342,1512,0852,0121,912
EBIT
17,13617,23017,81922,31822,76420,984
EBIT Margin
2.98%3.00%3.05%3.74%4.12%4.03%
Effective Tax Rate
27.04%26.79%25.55%23.07%22.72%23.16%